Terms: = Breast cancer AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S AND Prognosis
149 results:
1. Stellate Ganglion Destruction With Alcohol Versus Thermal Ablation for Chronic Post-Mastectomy Pain: A Randomized Trial.
Thabet TS; Khedr SA
Pain Physician; 2024 Feb; 27(2):E231-E238. PubMed ID: 38324788
[TBL] [Abstract] [Full Text] [Related]
2. Targeted Hyperbranched Nanoparticles for Delivery of Doxorubicin in breast cancer Brain Metastasis.
Lim M; Fletcher NL; Saunus JM; McCart Reed AE; Chittoory H; Simpson PT; Thurecht KJ; Lakhani SR
Mol Pharm; 2023 Dec; 20(12):6169-6183. PubMed ID: 37970806
[TBL] [Abstract] [Full Text] [Related]
3. Clinico-Pathological and Prognostic Significance of a Combination of Tumor Biomarkers in Iranian Patients With breast cancer.
Hassanzadeh Makoui M; Mobini M; Fekri S; Geranpayeh L; Moradi Tabriz H; Madjd Z; Kalantari E; Hosseini M; Hosseini M; Golsaz-Shirazi F; Jeddi-Tehrani M; Zarnani AH; Amiri MM; Shokri F
Clin Breast Cancer; 2024 Jan; 24(1):e9-e19.e9. PubMed ID: 37863762
[TBL] [Abstract] [Full Text] [Related]
4. Association of the m
Li Y; Cao J; Wang J; Wu W; Jiang L; Sun X
Cancer; 2024 Feb; 130(3):356-374. PubMed ID: 37861451
[TBL] [Abstract] [Full Text] [Related]
5. Patritumab Deruxtecan (her3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic breast cancer: A Multicenter, Phase I/II Trial.
Krop IE; Masuda N; Mukohara T; Takahashi S; Nakayama T; Inoue K; Iwata H; Yamamoto Y; Alvarez RH; Toyama T; Takahashi M; Osaki A; Saji S; Sagara Y; O'Shaughnessy J; Ohwada S; Koyama K; Inoue T; Li L; Patel P; Mostillo J; Tanaka Y; Sternberg DW; Sellami D; Yonemori K
J Clin Oncol; 2023 Dec; 41(36):5550-5560. PubMed ID: 37801674
[TBL] [Abstract] [Full Text] [Related]
6. her3/Akt/mTOR pathway is a key therapeutic target for the reduction of triple‑negative breast cancer metastasis via the inhibition of CXCR4 expression.
Takeda T; Tsubaki M; Genno S; Tokunaga K; Tanaka R; Nishida S
Int J Mol Med; 2023 Sep; 52(3):. PubMed ID: 37477145
[TBL] [Abstract] [Full Text] [Related]
7. HER-3 molecular classification, expression of PD-L1 and clinical importance in breast cancer.
Stanek L; Gurlich R; Whitley A; Tesarova P; Musil Z; Novakova L
Bratisl Lek Listy; 2022; 123(10):719-723. PubMed ID: 35913006
[TBL] [Abstract] [Full Text] [Related]
8. erbb3-Targeting Oncolytic Adenovirus Causes Potent Tumor Suppression by Induction of Apoptosis in cancer Cells.
Jung BK; Kim YJ; Hong J; Chang HG; Yoon AR; Yun CO
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806132
[TBL] [Abstract] [Full Text] [Related]
9. Expression of ERBB gene family in females with breast cancer and its correlation with clinicopathological characteristics of the disease.
Soosanabadi M; Ghahfarokhi AM; Pourghazi F; Ehtesham N; Mirfakhraie R; Atanesyan L; Keyhani E; Behjati F
Mol Biol Rep; 2022 Sep; 49(9):8547-8553. PubMed ID: 35763181
[TBL] [Abstract] [Full Text] [Related]
10. AC016405.3 functions as an oncogenic long non-coding RNA by regulating erbb3 via sponging miR-22-3p in breast cancer.
Wei M; Wang J; He Q; Liu L; Wang Z
J Clin Lab Anal; 2021 Sep; 35(9):e23952. PubMed ID: 34403532
[TBL] [Abstract] [Full Text] [Related]
11. Poor prognosis of male triple-positive breast cancer patients: a propensity score matched SEER analysis and molecular portraits.
Wang B; Wang H; Zhao A; Zhang M; Yang J
BMC Cancer; 2021 May; 21(1):523. PubMed ID: 33964913
[TBL] [Abstract] [Full Text] [Related]
12. Investigating mutations at the hotspot position of the ERBB2 and screening for the novel lead compound to treat breast cancer - a computational approach.
Thirumal Kumar D; Udhaya Kumar S; Magesh R; George Priya Doss C
Adv Protein Chem Struct Biol; 2021; 123():49-71. PubMed ID: 33485488
[TBL] [Abstract] [Full Text] [Related]
13. Heregulin-induced cell migration is prevented by trastuzumab and trastuzumab-emtansine in HER2+ breast cancer.
Mondaca JM; Guijarro ACC; Flamini MI; Sanchez AM
Breast Cancer Res Treat; 2021 Apr; 186(2):363-377. PubMed ID: 33474679
[TBL] [Abstract] [Full Text] [Related]
14. Overexpression of β-Arrestins inhibits proliferation and motility in triple negative breast cancer cells.
Bostanabad SY; Noyan S; Dedeoglu BG; Gurdal H
Sci Rep; 2021 Jan; 11(1):1539. PubMed ID: 33452359
[TBL] [Abstract] [Full Text] [Related]
15. EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer.
D'Agostino D; Gentile R; Ponziani S; Di Vittorio G; Dituri F; Giannelli G; Rossi C; Marzullo L; Giansanti F; De Laurenzi V; Iacobelli S; Ippoliti R; Capone E; Sala G
Oncol Rep; 2021 Feb; 45(2):776-785. PubMed ID: 33416143
[TBL] [Abstract] [Full Text] [Related]
16. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany.
Huebner H; Kurbacher CM; Kuesters G; Hartkopf AD; Lux MP; Huober J; Volz B; Taran FA; Overkamp F; Tesch H; Häberle L; Lüftner D; Wallwiener M; Müller V; Beckmann MW; Belleville E; Ruebner M; Untch M; Fasching PA; Janni W; Fehm TN; Kolberg HC; Wallwiener D; Brucker SY; Schneeweiss A; Ettl J
BMC Cancer; 2020 Nov; 20(1):1091. PubMed ID: 33176725
[TBL] [Abstract] [Full Text] [Related]
17. A structural view of PA2G4 isoforms with opposing functions in cancer.
Stevenson BW; Gorman MA; Koach J; Cheung BB; Marshall GM; Parker MW; Holien JK
J Biol Chem; 2020 Nov; 295(47):16100-16112. PubMed ID: 32952126
[TBL] [Abstract] [Full Text] [Related]
18. Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab.
Li J; Ma M; Yang X; Zhang M; Luo J; Zhou H; Huang N; Xiao F; Lai B; Lv W; Zhang N
Mol Cancer; 2020 Sep; 19(1):142. PubMed ID: 32917240
[TBL] [Abstract] [Full Text] [Related]
19. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
Kurozumi S; Alsaleem M; Monteiro CJ; Bhardwaj K; Joosten SEP; Fujii T; Shirabe K; Green AR; Ellis IO; Rakha EA; Mongan NP; Heery DM; Zwart W; Oesterreich S; Johnston SJ
Breast Cancer Res; 2020 Aug; 22(1):85. PubMed ID: 32782013
[TBL] [Abstract] [Full Text] [Related]
20. Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients.
Skriver SK; Jensen MB; Eriksen JO; Ahlborn LB; Knoop AS; Rossing M; Ejlertsen B; Laenkholm AV
Breast Cancer Res Treat; 2020 Nov; 184(1):123-133. PubMed ID: 32748297
[TBL] [Abstract] [Full Text] [Related]
[Next]
